[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Benoit Corven C, Carvalho P, Prost C, Verret JL, Saiag P, Noblesse I, Bedane C, Chosidow O, Young P, Roujeau JC, Joly P: [Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)]. Ann Dermatol Venereol; 2003 Jan;130(1 Pt 1):13-5
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)].
  • [Transliterated title] Traitement du pemphigus vulgaire par le protocole Lever faible.
  • INTRODUCTION: The so-called "Lever scheme" therapeutic regimen has been proposed in the borderline forms of pemphigus to reduce the side effects of systemic corticosteroids.
  • The criteria for inclusion were the clinical diagnosis of pemphigus, confirmed by histological examination and direct immunofluorescence and first line therapy using the "Lever scheme" protocol, combining 40 mg of prednisone on alternate days and 100 mg/day of azathioprine.
  • Three of these patients died: a bed-ridden patient, a patient exhibiting a metastatic bronchial carcinoma and a hypertensive patient who died following a hemorrhagic cerebral vascular accident.
  • Twelve patients (54 p. 100) were weaned off treatment after a mean duration of 2.9 years.
  • [MeSH-major] Azathioprine / administration & dosage. Glucocorticoids / administration & dosage. Immunosuppressive Agents / administration & dosage. Pemphigus / drug therapy. Prednisone / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Pemphigus.
  • Genetic Alliance. consumer health - Pemphigus vulgaris.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12605150.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


2. Terashima T, Matsuzaki T, Kawada I, Nishida J, Tanaka Y, Morishita T, Takeyasu Y, Yamane GY, Uchiyama T: Tongue metastasis as an initial presentation of a lung cancer. Intern Med; 2004 Aug;43(8):727-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 63-year-old man had a submucosal tumor on the left posterolateral aspect of the tongue and a biopsy specimen of the tongue tumor showed poorly differentiated squamous cell carcinoma.
  • A chest X-ray showed a mass in the right lung and cytological examination of the specimen obtained by bronchial brushing showed poorly differentiated squamous cell carcinoma, whose appearance was similar to that of the tongue.
  • Based on these findings, the tongue lesion was diagnosed a metastatic tumor from the lung cancer.
  • The patient received radiation therapy combined with systemic chemotherapy, however, he died 5 months after the diagnosis of lung cancer.
  • An autopsy revealed a lung cancer in the right lower lobe with metastatic tumors in the tongue, right middle lobe, left upper lobe, liver, adrenal gland, pericardium, heart, and subcutaneous tissues.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Lung Neoplasms / pathology. Tongue Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Tongue cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15468975.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Merkl J, Poppert H, Hein R, Ring J: [Acral scleroderma presenting simultaneously with small-cell bronchial carcinoma: a paraneoplastic disease?]. J Dtsch Dermatol Ges; 2005 Feb;3(2):117-9
Genetic Alliance. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acral scleroderma presenting simultaneously with small-cell bronchial carcinoma: a paraneoplastic disease?].
  • [Transliterated title] Gleichzeitige Manifestation einer Akrosklerodermie und eines kleinzelligen Bronchial-Karzinoms: Ein paraneoplastisches Syndrom?
  • In the case of dermatomyositis, a malignant tumor is viewed as a possible trigger of the collagen disease; in contrast, scleroderma is suspected of causing tumors because of the long-term tissue fibrosis.
  • A 68-year-old woman presented with acral scleroderma but already had metastatic bronchial carcinoma without evidence for previous pulmonary fibrosis.
  • Impressive in this case is the fact that acral scleroderma definitely developed after the malignant tumor but before treatment, so that both fibrosis of the lung and side effects of chemotherapy and radiation can be excluded as triggers.
  • [MeSH-major] Bronchial Neoplasms / pathology. Bronchial Neoplasms / secondary. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / secondary. Hand / pathology. Paraneoplastic Syndromes / pathology. Scleroderma, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351015.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Osaki T, Oyama T, Takenoyama M, Taga S, So T, Yamashita T, Nakata S, Nakanishi R, Yasumoto K: Feasibility of induction chemotherapy using bronchial arterial infusion for locally advanced non-small cell lung cancer: a pilot study. Surg Today; 2002;32(9):772-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of induction chemotherapy using bronchial arterial infusion for locally advanced non-small cell lung cancer: a pilot study.
  • PURPOSE: We examined the feasibility and effectiveness of bronchial arterial infusion (BAI) as induction chemotherapy before surgery for locally advanced non-small cell lung cancer (NSCLC).
  • METHODS: Eighteen patients with locally advanced NSCLC were given BAI consisting of cis-diamminedichloroplatinum (CDDP) (50-100 mg/m(2)) as induction chemotherapy before surgery (induction BAI).
  • Six patients with clinical stage IIIA cancer had bulky N2 metastatic lymph nodes, and 12 patients with clinical stage IIIB cancer had T4 disease.
  • RESULTS: Of the 18 patients, 12 (67%) showed a partial response to the BAI therapy.
  • There were no serious BAI therapy-related complications or postoperative deaths.
  • The 5-year survival rate of the 18 patients was 35.7% and the median survival time (MST) was 19.4 months.
  • CONCLUSION: Based on our preliminary findings, BAI with CDDP as induction chemotherapy is feasible and may be an effective therapeutic modality for locally advanced NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Feasibility Studies. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Pilot Projects. Remission Induction


5. Serke M, Allica E, Wolf M, Schönfeld N, Kaiser D, Loddenkemper R: [Non-small-cell bronchial carcinoma with pathological N2 involvement: adjuvant radiotherapy versus adjuvant chemo-radiotherapy]. Kongressbd Dtsch Ges Chir Kongr; 2001;118:606-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-small-cell bronchial carcinoma with pathological N2 involvement: adjuvant radiotherapy versus adjuvant chemo-radiotherapy].
  • [Transliterated title] Nicht-kleinzelliges Bronchialkarzinom mit pathologischem N2-Befall: Adjuvante Radiotherapie versus adjuvante Chemo-Radiotherapie.
  • Fifty-eight patients, 28 of them included in a German multicenter study, were treated either with radiotherapy (5 x 2 Gy/50 Gy) or combined radio-chemotherapy (cisplatin 75 mg/m2 d1 in cases with pneumonectomy etoposide 120 mg/m2 d1-3) and Ifosfamid 1.5 mg/m2 d1-4, 3 cycles) following surgery in pN2-NSCLC.
  • Metastatic disease or local failure was seen in 24 patients (43%), in the majority with distant metastasis (n = 21), in 4 patients combined local and distant failure.
  • Time to progression (TTP) was 27 to 1172 days, median 244 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11824325.001).
  • [Journal-full-title] Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress
  • [ISO-abbreviation] Kongressbd Dtsch Ges Chir Kongr
  • [Language] GER
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  •  go-up   go-down


6. Sculier JP, Berghmans T, Paesmans M, Branle F, Lemaitre F, Mascaux C, Meert AP, Steels E, Vallot F, Lafitte JJ: [The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers]. Rev Med Brux; 2001 Dec;22(6):477-87
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers].
  • [Transliterated title] La place de la chimiothérapie dans le traitement des cancers bronchiques non à petites cellules, non métastatiques.
  • A systematic review of the literature about the role of chemotherapy in comparison to local therapies--surgery or radiotherapy--in non-small cells lung cancers has identified 35 randomised trials.
  • The aggregation (meta-analysis) shows a significant effect of survival improvement by chemotherapy, whatever all indications are considered or subgroups like adjuvant chemotherapy to surgery, neoadjuvant chemotherapy, concomitant radio-chemotherapy and induction chemotherapy prior to thoracic irradiation.
  • [MeSH-major] Carcinoma, Bronchogenic / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Belgium / epidemiology. Combined Modality Therapy. Humans. Neoadjuvant Therapy / methods. Neoadjuvant Therapy / standards. Neoplasm Staging. Pneumonectomy / standards. Radiotherapy, Adjuvant / standards. Research Design / standards. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11811043.001).
  • [ISSN] 0035-3639
  • [Journal-full-title] Revue médicale de Bruxelles
  • [ISO-abbreviation] Rev Med Brux
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] Belgium
  •  go-up   go-down


7. Pujol JL, Quantin X, Jacot W, Serre A, Fayolle V: [Small cell lung cancer (CPC). Small cell bronchial carcinoma: therapeutic management]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S198-16S204
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell lung cancer (CPC). Small cell bronchial carcinoma: therapeutic management].
  • Small cell bronchial carcinoma holds a prominent position among malignant tumours on account of its high incidence and the problems of its treatment.
  • The diagnostic approach is dictated by the concern not to overlook any metastatic sites.
  • Small cell bronchial carcinoma is often metastatic at the time of diagnosis and should be considered an actual or potential systemic disease.
  • Chemotherapy is therefore the basis of treatment.
  • It should consist of at least a two drug regime combining cisplatin and etoposide.
  • In extensive disease, that is when all the disease cannot be contained within one irradiation field, chemotherapy alone is recommended.
  • In limited disease combined simultaneous radiotherapy and chemotherapy is recommended.
  • Prophylactic cranial irradiation is indicated in patients in complete remission after chemotherapy.
  • The therapeutic armamentarium has recently been enlarged by the development of new antineoplastic drugs and the development of non-toxic targeted agents including those influencing angiogenesis.
  • The understanding of the specific mechanisms of drug resistance and the study of the tumour phenotypes and genotypes will allow, in the future, the development of treatments adapted for each patient.
  • [MeSH-major] Carcinoma, Bronchogenic / therapy. Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268358.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 34
  •  go-up   go-down


8. Boutemy M, Mispelaere D, Krzisch C, Jounieaux V: [Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma]. Rev Mal Respir; 2005 Jun;22(3):413-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
  • [Transliterated title] Evaluation de la chimiothérapie associant vinorelbine-ifosfamide-cisplatine dans le traitement des cancers bronchiques non à petites cellules métastatiques.
  • INTRODUCTION: In France, cancer of the bronchus is responsible for 25,000 deaths per year.
  • Non small cell lung cancer (NSCLC) represents 80% of bronchial carcinoma of which 40-50% are mefastatic at the time of diagnosis.
  • At present, although the therapeutic benefits are modest, it is now recognised that combination chemotherapy including platinum salts improves the survival of these patients.
  • METHODS: We analysed retrospectively a cohort of 57 patients suffering from stage IV NSCLC treated with chemotherapy combining cisplatin (80 mg/rn2 on day 1), vinorelbine (25 mg/rn2 on days 1 and 8) and ifosfamide (3000 mg/in 2 on day 1), (NIP), repeated every 21 days.
  • All patients were studied in terms of toxicity and overall survival but only 40 (70%) were able to be evaluated in terms of response to treatment (on account of having received more than three cycles of NIP chemotherapy).
  • For the 40 patients for whom chemotherapy was evaluable, the objective response rate was 20%.
  • CONCLUSION: Treatment of stage IV NSCLC with NIP chemotherapy is effective and improves the survival of these patients independently of other prognostic factors such as age, the presence of cerebral metastases, performance status, histological type, the number of metastatic sites or the serum LOH level.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Bronchogenic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cohort Studies. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Life Tables. Male. Middle Aged. Retrospective Studies. Smoking / adverse effects. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227927.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Pérol M: [First-line treatment of metastatic non-small cell lung cancers]. Rev Pneumol Clin; 2004 Nov;60(5 Pt 2):3S51-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [First-line treatment of metastatic non-small cell lung cancers].
  • [Transliterated title] Traitement de première ligne des cancers bronchiques non à petites cellules métastatiques.
  • The first-line treatment of non-small cell bronchial cancers at the metastatic stage relies on chemotherapy, the impact of which, in terms of survival in comparison with palliative care alone, has been confirmed by several meta-analyses.
  • The recent development of new drugs (vinorelbine, gemcitabine, paclitaxel, docetaxel) that benefit from an improved efficacy-toxicity ratio, has led to the individualisation, as treatment standard in patients in a general state of good health, of bitherapies based on the combination of a platinum salt and recent active drugs.
  • The choice of the first-line therapy in a given patient will be based essentially on the differences in toxicity profiles among the therapeutic regimens, taking into account the frequent co-morbidities in this population, the modalities of administration and the perspectives of second-line therapy.
  • The patients with an altered general state of health (PS 2) will benefit from adapted treatment based on active monotherapy or bitherapy without cisplatin.
  • The prolongation of the first-line therapy over and above 4 cycles following maximal reduction of the tumour does not provide enhanced survival and considerably increases toxicity.
  • The recent cytotoxic agents appear to provide a real progress, although modest in the treatment of metastatic NSCBC, progress which is visible considering the proportion of patients still living in the long term.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15536354.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 11
  •  go-up   go-down


10. Bartsch V: [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma]. Onkologie; 2006 Mar;29 Suppl 1:1-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
  • [Transliterated title] Orales Vinorelbin: Pharmakologie und Behandlungsergebnisse beim nichtkleinzelligen Bronchialkarzinom und Mammakarzinom.
  • The development of an oral formulation of vinorelbine (Navelbine softgelatine capsules, Pierre Fabre Pharma, Freiburg i.Br., Germany) represents a significant advance in the treatment of patients with cancer.
  • Oral chemotherapy is more convenient for the patients and brings significant time savings.
  • However, if severe neutropenia is encountered during the first cycle, treatment is continued with weekly doses of 60 mg/m(2).
  • Several clinical studies have demonstrated that the new oral formulation of vinorelbine can be safely administered, even to elderly patients, and is comparable in activity to intravenous vinorelbine in advanced non-small cell lung cancer (NSCLC) and metastatic breast cancer (MBC).
  • A randomized phase II comparison of oral vinorelbine at the recommended dose schedule vs. intravenous vinorelbine at 30 mg/(2) in patients with advanced NSCLC found no significant differences in response rate, progression-free and overall survival between the two treatments.
  • In studies of combination chemotherapy using vinorelbine plus cisplatin or carboplatin in advanced NSCLC, or vinorelbine plus taxanes, capecitabine,epirubicin, or the monoclonal HER2/neu antibody trastuzumab in MBC, intravenous vinorelbine could be completely or partially replaced by oral vinorelbine, resulting in maintained efficacy, good tolerability and improved patient convenience.
  • Metronomic chemotherapy is a new treatment approach designed to maximize the antiangiogenic effect.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Availability. Chemotherapy, Adjuvant. Clinical Trials as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16534241.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  • [Number-of-references] 83
  •  go-up   go-down


11. Rosell R, Moran T, Fernanda Salazar M, Mendez P, De Aguirre I, Ramirez JL, Isla D, Cobo M, Camps C, Lopez-Vivanco G, Alberola V, Taron M: The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S131-16S136
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.
  • This review highlights the numerous molecular biology findings in the field of lung cancer with potential therapeutic impact in both the near and distant future.
  • Abundant pre-clinical and clinical data indicate that BRCA1 mRNA expression is a differential modulator of chemotherapy sensitivity.
  • Low levels predict cisplatin sensitivity and antimicrotubule drug resistance, and the opposite occurs with high levels.
  • For the first time, EGFR mutations have been shown to predict dramatic responses in metastatic lung adenocarcinomas, with a threefold increase in time to progression and survival in patients receiving EGFR tyrosine-kinase inhibitors.
  • Understanding the relevance of these findings can help to change the clinical practice in oncology towards customizing chemotherapy and targeted therapies, leading to improvement both in survival and in cost-effectiveness.
  • [MeSH-major] Carcinoma, Bronchogenic / drug therapy. Carcinoma, Bronchogenic / mortality. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality


12. Mornex F, Martin E, Bellière A, Milleron B, Van Houtte P, Chapet O: [Locally advanced non-small-cell bronchial cancer: role of exclusive chemoradiotherapy]. Cancer Radiother; 2002 Nov;6 Suppl 1:117s-124s
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced non-small-cell bronchial cancer: role of exclusive chemoradiotherapy].
  • [Transliterated title] Cancer bronchique non à petites cellules localement évolué: place de la chimioradiothérapie exclusive.
  • Surgery remains the reference treatment but only a small minority of patients (about 25%) present with operable disease.
  • The post-surgical 5-year survival is only 25%, providing the rationale for the current research on adjuvant treatments for control of both local and metastatic disease.
  • In that context, the combination of radiotherapy and chemotherapy, commonly referred to as chemo-radiotherapy, has assumed considerable importance: either exclusively in inoperable patients (inoperable tumour or patients inoperable for medical reasons), or pre-operatively.
  • This article reviews the results of the pivotal definitive chemoradiotherapy studies in non-metastatic non-small-cell lung cancer.
  • An increased toxicity is observed, and the advent of conformal therapy may allow another survival gain.
  • Optimal treatments integration will be necessary.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Invasiveness. Organoplatinum Compounds / pharmacology. Organoplatinum Compounds / therapeutic use. Prognosis. Radiation-Sensitizing Agents / pharmacology. Radiation-Sensitizing Agents / therapeutic use. Radiotherapy Dosage. Radiotherapy, Conformal. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12587390.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Radiation-Sensitizing Agents
  • [Number-of-references] 37
  •  go-up   go-down


13. Friedrich RE: Mental neuropathy (numb chin syndrome) leading to diagnosis of metastatic mediastinal cancer. Anticancer Res; 2010 May;30(5):1819-21
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mental neuropathy (numb chin syndrome) leading to diagnosis of metastatic mediastinal cancer.
  • Plain radiographs and computerised tomography (CT) scans revealed the mental foramen on the top of the toothless mandible and a symmetrically depicted mandibular canal.
  • Diagnosis was small-cell bronchial carcinoma (extensive disease, stage grouping II B, Marburg classification).
  • Palliative chemotherapy was ineffective and the patient died with evidence of tumour progression.
  • [MeSH-minor] Aged. Antineoplastic Agents / pharmacology. Carcinoma / diagnosis. Carcinoma / pathology. Disease Progression. Foreign-Body Reaction. Humans. Jaw / pathology. Male. Neoplasm Metastasis. Palliative Care. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592385.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Pester U, Günzel T, Franzen A: [Small cell carcinoma of parotid gland--a case report]. Laryngorhinootologie; 2008 Apr;87(4):265-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of parotid gland--a case report].
  • [Transliterated title] Kleinzelliges Karzinom der Glandula parotis--ein Fallbeispiel.
  • BACKGROUND: Small cell carcinoma of the major salivary glands are very seldom.
  • If there is such a tumor always have in mind that it can be a metastatic process of another small cell carcinoma in other locations of the body.
  • That's why first of all a primary in the bronchial system has to be excluded with special diagnostics.
  • CASE REPORT: We present the case of a 72-year-old woman suffering from a small cell carcinoma of Parotid gland.
  • Because a surgical therapy was impossible she underwent a radiotherapy.
  • CONCLUSION: First choice for therapy of tumors of the major salivary glands is surgical therapy in combination with radiation/chemotherapy.
  • If this is not possible a primary radiotherapy sometimes in combination with chemotherapy seems to be another therapeutic option.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Magnetic Resonance Imaging. Parotid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038375.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Kambayashi T, Ri M, Yanagihara K, Miyahara R, Bando T, Hasegawa S, Inui K, Wada H: [A case of endobronchial squamous cell lung cancer successfully treated with weekly chemotherapy of carboplatin and paclitaxel]. Gan To Kagaku Ryoho; 2003 Jun;30(6):841-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of endobronchial squamous cell lung cancer successfully treated with weekly chemotherapy of carboplatin and paclitaxel].
  • A 69-year-old man had undergone low anterior resection and a right lobe resection of the liver for rectum cancer and metastatic liver tumor at the age of 66 years.
  • He was initially treated with weekly chemotherapy with carboplatin (AUC 1.25) and paclitaxel (70 mg/m2).
  • The endobronchial tumor was markedly reduced in size after 2 weeks of the chemotherapy.
  • Furthermore, after 6 weeks of the chemotherapy, the tumor had disappeared completely, and 11 days later, lower division segmentectomy and hilar and mediastinal lymph node dissection were performed.
  • The patient has continued to receive chemotherapy as an outpatient and has been well without recurrence of any metastases for over 16 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchial Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Drug Administration Schedule. Humans. Lymphatic Metastasis. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12852353.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 8
  •  go-up   go-down


16. Lüdike A, Knolle J, Schön R, Hinze P, Hofmann HS, Schreiber J: [Primary pulmonary rhabdomyosarcoma as a rare differential diagnosis of small cell lung cancer]. Pneumologie; 2005 Jul;59(7):456-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination revealed a typical small cell carcinoma and histological examination of biopsies obtained from a tumor in the left upper lobe of the lung was compatible with a small cell carcinoma.
  • Despite chemotherapy there was a progressive tumor growth.
  • Bronchial biopsies again showed a small cell tumor, although immunohistochemistry proved it to be a pleomorphic rhabdomyosarcoma.
  • Due to the progressive tumor growth with necrosis and superinfection and a lack of further metastases lobectomy of the left upper lobe was performed, complicated by postoperative pleural empyema, limiting the possibilities of adjuvant therapy.
  • Laminectomy and extirpation of the spinal metastases, local radiotherapy and chemotherapy with iphosphamide and doxorubicine led to partial remission and clinical improvement for few months only.
  • The patient died from metastatic primary rhabdomyosarcoma of the lung.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Lung Neoplasms / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Recurrence

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047279.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Uberall I, Kolek V, Klein J, Krejcí V, Stastná J, Radová L, Skarda J, Fridman E: The immunohistochemical expression of BNIP3 protein in non-small-cell lung cancer: a tissue microarray study. APMIS; 2010 Aug;118(8):565-70
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The immunohistochemical expression of BNIP3 protein in non-small-cell lung cancer: a tissue microarray study.
  • Drug resistance is one of the reasons for chemotherapy failure in non-small-cell lung carcinoma (NSCLC).
  • One of the major mechanisms of drug resistance is the inhibition of chemotherapy-induced apoptosis.
  • One of the non-caspase types of cell death is autophagy.
  • In the present study, we investigated the immunohistochemical expression and subcellular localization of BNIP3 in a series of early- and late-stage non-small-cell lung carcinomas and normal bronchial tissues, and correlated this expression with the occurrence of metastasis and survival.
  • This BNIP3 positivity did not correlate with histological grade, stage, histology type, metastatic potential, or expression of BNIP3 according to median values.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / chemistry. Lung Neoplasms / chemistry. Membrane Proteins / analysis. Proto-Oncogene Proteins / analysis. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666737.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BNIP3 protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


18. Lesinski-Schiedat A, Hemmanouil I, Sauer-Gönen M, Flemming P, Freihorst I, Kempf HG, Lenarz T: [Malignant transformation of a juvenile papilloma in a 11 year old boy]. Laryngorhinootologie; 2005 Aug;84(8):602-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Often the entity shows an elongated recurrent course of disease with an expansion into the tracheo-bronchial system.
  • Sporadic malignant transformation in adults with a papilloma was reported after treatment with radiotherapy alone or in combination with the intake of additional toxins (e. g. nicotine).
  • The multiple laser surgical procedures and a therapy with interferon resulted in a short-term remissions.
  • Seven months after the first diagnosis of the papilloma a regional metastatic squamous cell carcinoma was found.
  • In spite of combined radiotherapy and chemotherapy the boy died 11 months later.
  • CONCLUSIONS: The spontaneous malignant transformation of a juvenile papilloma in a squamous cell carcinoma is extremely rare.
  • The surgical intervention as well the radiotherapy and chemotherapy using interferon was unsuccessful due to the high grade of malignancy.
  • In view of the very short time interval between first diagnosis of juvenile papilloma and the subsequent malignant transformation, one must consider either the potential presence of a very aggressive form of papilloma or alternative two coincident independent diseases.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Laryngeal Neoplasms / pathology. Papilloma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Interferons / therapeutic use. Magnetic Resonance Imaging. Male. Remission Induction. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080063.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  •  go-up   go-down


19. Zieliński M, Hauer L, Hauer J, Nabiałek T, Szlubowski A, Pankowski J: Non-small-cell lung cancer restaging with transcervical extended mediastinal lymphadenectomy. Eur J Cardiothorac Surg; 2010 Apr;37(4):776-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1 January 2004 to 30 April 2009, 63 patients who underwent induction chemotherapy or chemo-radiotherapy for N2 and N2/3 metastatic nodes discovered preoperatively were restaged.
  • There were 45 squamous cell carcinomas, 13 adenocarcinomas, one pleomorphic carcinoma and four NSCLCs.
  • A total of 54 patients underwent neoadjuvant chemotherapy and nine chemo-radiotherapy.
  • Seven patients had mediastinoscopy before neoadjuvant therapy.
  • Metastatic nodes were discovered in 22 patients including three patients with N3 nodes and 19 patients with N2 nodes.
  • There was no postoperative mortality, two bronchial fistulas were developed (after inferior bilobectomy and right pneumonectomy; the second one healed spontaneously) and there were no other serious complications.
  • (1) The results of TEMLA in restaging of NSCLC (N2/3) patients after induction chemotherapy or chemo-radiotherapy were significantly better than those achieved with remediastinoscopy, EBUS and positron emission tomography/computed tomography (PET/CT). (2) The results of future studies will show if TEMLA should be considered the gold standard of mediastinal nodal restaging after neoadjuvant therapy in patients with NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinoscopy. Mediastinum. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Thoracotomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur J Cardiothorac Surg. 2010 Apr;37(4):780-1 [20036137.001]
  • (PMID = 20044265.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Niang A, Bonnichon A, Ba-Fall K, Dussart C, Camara P, Vaylet F, Mbaye PS, L'Her P, Sane M, Margery J: [Lung cancer in Senegal]. Med Trop (Mars); 2007 Dec;67(6):651-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Le cancer bronchique au Sénégal.
  • The purpose of this prospective study was to analyze clinical, therapeutic, and prognostic features of lung cancer patients treated at the Principal Hospital in Dakar between 2002 and 2007.
  • Histological samples were obtained in 79.1% of cases by bronchial fibroscopy (n=33), CT-guided transthoracic needle biopsy (n=17), or from a metastatic site (n=7).
  • The histological diagnosis was squamous cell carcinoma in 23 cases, adenocarcinoma in 14, large-cell carcinoma in 17, small-cell lung cancer in 2, and bronchiolo-alveolar cancer in 1.
  • In the remaining cases management consisted of chemotherapy in 22 cases, radiotherapy for pain relief in 5, and surgery in 1.
  • Median survival was 7 or 3 months depending on whether or not chemotherapy was performed.
  • The much higher rate of histological diagnosis than in the sub-region is due mainly to the availability of trained personnel with access to bronchial endoscopy and CT-scan needle biopsy since September 2003.
  • Administration of cytotoxins is feasible but the cost is excessive due to the lack of universal health care coverage: two-thirds of cases were abandoned whereas chemotherapy significantly improved median survival by 4 months (p < 0.0001).
  • It is urgent to develop therapeutic standards adapted to the African socio-economic setting as well as an anti-tobacco prevention policy.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / therapy. Lung Neoplasms / epidemiology. Lung Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biopsy / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Prospective Studies. Senegal / epidemiology. Smoking / adverse effects. Smoking / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300532.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Katsimbri PP, Bamias AT, Froudarakis ME, Peponis IA, Constantopoulos SH, Pavlidis NA: Endobronchial metastases secondary to solid tumors: report of eight cases and review of the literature. Lung Cancer; 2000 May;28(2):163-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since 1990 we have treated eight patients with EBM secondary to renal adenocarcinoma (three cases), colon adenocarcinoma (two cases), gastric adenocarcinoma (one case), bladder carcinoma (one case) and basal cell carcinoma (one case).
  • Endobronchial lesions were detected by bronchoscopy and their metastatic nature was confirmed histopathologically in all eight cases.
  • Five patients were treated with external radiotherapy with symptomatic improvement while two patients had chemotherapy and one patient underwent surgical resection of the metastasis.
  • Systemic treatment was used in six cases with no significant effect on EBM.
  • Local treatment may result in symptomatic improvement but prognosis is generally poor averaging 1-2 years in most series.
  • [MeSH-major] Bronchial Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / pathology. Diagnosis, Differential. Female. Humans. Kidney Neoplasms / pathology. Male. Middle Aged. Prognosis. Stomach Neoplasms / pathology. Survival Analysis. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2001 Feb-Mar;31(2-3):351-2 [11305261.001]
  • (PMID = 10717334.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] IRELAND
  • [Number-of-references] 26
  •  go-up   go-down


22. Fournel C, Bertoletti L, Nguyen B, Vergnon JM: Endobronchial metastases from colorectal cancers: natural history and role of interventional bronchoscopy. Respiration; 2009;77(1):63-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastases from colorectal cancers can be treated either surgically or with chemotherapy in order to improve survival.
  • METHODS: This retrospective study included 24 patients who underwent an interventional bronchoscopy procedure between 1988 and 2006.
  • Assessment of the natural history of metastatic colorectal carcinoma, therapeutic options and survival associated with endobronchial metastases are reported.
  • The median overall survival was 70 months (range 23-245) and 14 months once the endobronchial metastase(s) had been diagnosed.
  • CONCLUSION: Endobronchial metastases occur relatively late in patients with a metastatic colorectal neoplasm.
  • Palliative treatment with interventional bronchoscopy to prevent asphyxia is a safe and effective method that may improve the quality of life in these patients.
  • [MeSH-major] Adenocarcinoma / therapy. Bronchial Neoplasms / therapy. Bronchoscopy. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18812690.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Gounant V, Milleron B, Assouad J, Gligorov J, Lavole A, Wislez M, Brian E, Bazelly B, Grunenwald D: [Bevacizumab and invasive procedures: practical recommendations]. Rev Mal Respir; 2009 Feb;26(2):221-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As first line chemotherapy Bevacizumab, associated with a platinum based regime, improves survival in patients with metastatic, non small cell, non epidermoid bronchial carcinoma.
  • This treatment produces specific secondary effects related to its anti-angiogenic action.
  • We depend, therefore, principally on studies of neo-adjuvant chemotherapy in metastatic colo-rectal cancer prior to excision of hepatic metastases and on our own experience of excision of pulmonary metastases from solid tumours treated with bevacizumab.
  • We recommend a delay of 2 days between implantation of an intravenous device and the initiation of bevacizumab, a delay of at least 5 weeks between the last injection of bevacizumab and invasive surgery and a delay of 4 weeks between surgery and the initiation of bevacizumab treatment.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Bronchoscopy. Catheterization, Central Venous. Cicatrix / prevention & control. Fluoroscopy. Humans. Neoplasms / surgery. Skin Ulcer / prevention & control. Time Factors. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319116.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


24. Zimmermann FB, Molls M, Jeremic B: Treatment of recurrent disease in lung cancer. Semin Surg Oncol; 2003;21(2):122-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent disease in lung cancer.
  • Recurrence is a common event after treatment of lung cancer.
  • Retreatment options depend on previous therapies, location of recurrence, and physical condition of the patient.
  • Locoregional relapse can be treated the same way as initial lung cancer, including surgery, radiotherapy (RT), and chemotherapy (CHT), or combined treatment.
  • In the former case, external beam RT was particularly effective in isolated bronchial stump recurrences, with median survival time of approximately 28.5 months and a 5-year survival of approximately 31.5%.
  • In the latter case, reirradiation, generally with endobronchial brachytherapy, was successful in palliation of intrathoracic symptoms (in at least two-thirds of cases), carrying a low incidence of radiation pneumonitis (up to 5%) although cumulative doses went up to 120-150 Gy.
  • Finally, CHT has been used in relapsed/refractory advanced or metastatic non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with the major emphasis on the third-generation drugs that show good response after previously used platinum-based CHT.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14508862.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


25. Gregorc V, Darwish S, Ludovini V, Pistola L, De Angelis V, Mihaylova Z, Bellezza G, Sidoni A, Cavaliere A, Bucciarelli E, Massaro G, Tonato M: The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer. Lung Cancer; 2003 Dec;42(3):275-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The aim of this study was to evaluate the impact of Bcl-2, retinoblastoma (Rb) and p53 proteins on overall survival of 102 patients with locally advanced and metastatic NSCLC who underwent cisplatin-based chemotherapy.
  • MATERIALS AND METHODS: Paraffin-embedded bronchial biopsy and fine-needle biopsy specimens were evaluated by an immunostaining method.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14644514.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


26. Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, Murata Y, Tsuta K, Nishiwaki Y, Kodama T, Ochiai A: Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg; 2005 Jan;79(1):278-82; discussion 283
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pulmonary metastasectomy is a standard method of treatment for selective pulmonary metastases of colorectal cancer.
  • However, the pathologic factors of metastatic lesions that affect survival and tumor recurrence after pulmonary resection are less well defined.
  • METHODS: Between July 1992 and November 2002, 89 patients underwent the complete resection of pulmonary metastases of primary colorectal carcinoma, and we pathologically reviewed the surgical specimens of 136 metastatic lesions from these patients.
  • CONCLUSIONS: The morphologic features of ASFC and vascular invasion at metastatic sites are prognostic factors for colorectal cancer patients who have undergone pulmonary metastasectomy.
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Adult. Aged. Aged, 80 and over. Blood Vessels / pathology. Bronchial Neoplasms / secondary. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Hepatectomy. Humans. Life Tables. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pleural Neoplasms / secondary. Pneumonectomy / methods. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Analysis. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Apr;81(4):1547-8; author reply 1548 [16564324.001]
  • (PMID = 15620957.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 19
  •  go-up   go-down


27. Borrás-Blasco J, Rosique-Robles D, Giner-Marco V, Galan-Brotons A, Casterá E, Costa S: Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid. J Clin Pharm Ther; 2007 Dec;32(6):651-4
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report a case of possible delayed-onset osteonecrosis of the jaw after treatment with zoledronic acid.
  • CASE SUMMARY: A 53-year-old white man with no history of allergic drug reactions had been diagnosed as having bronchial epidermoid carcinoma.
  • He received therapy with docetaxel and zoledronate.
  • Because of metastatic progression of the disease, he started treatment with irinotecan and zoledronate.
  • One year after the last cycle of bisphosphonate therapy, the patient had one tooth extracted.
  • Surgical treatment was chosen, with debridement and a mucosal flap, complemented with antibiotic therapy.
  • DISCUSSION: Osteonecrosis of the jaws has recently emerged as a potential complication of bisphosphonate therapy in patients with metastatic cancer undergoing dental surgery.
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021344.001).
  • [ISSN] 0269-4727
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


28. Lobaplatin: D 19466. Drugs R D; 2003;4(6):369-72
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lobaplatin [D 19466] is a platinum complex with DNA alkylating activity that was developed by ASTA Medica (Degussa) for the treatment of cancer.
  • ASTA Medica discontinued development of lobaplatin, and subsequent development of the compound became the responsibility of Zentaris AG (AEterna Laboratories), which was formed in 2001 from the biopharmaceutical, inhalation technology and gene therapy activities of ASTA Medica.
  • Cisplatin, one of the original platinum compounds, has had a major impact on the treatment of solid tumours such as germ cell cancer, ovarian cancer, bladder cancer and bronchial carcinoma, but its clinical usefulness is limited by renal, neurological and gastrointestinal toxicity.
  • This has led to the development of second- and third-generation platinum analogues, such as lobaplatin, with reduced toxicity and a better therapeutic index.
  • The technology transfer agreement provides for Zentaris to receive a one-time payment to the amount of 4.5 million Canadian dollars.
  • Lobaplatin has been approved in China for the treatment of chronic myelogenous leukaemia (CML) and inoperable, metastatic breast and small cell lung cancer.
  • Lobaplatin has also completed phase II clinical trials in the US, Australia, EU, Brazil and South Africa for the treatment of various cancers, including breast, oesophageal, lung and ovarian cancers as well as CML.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cyclobutanes / therapeutic use. Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584968.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cyclobutanes; 0 / Organoplatinum Compounds; OX5XK1JD8C / lobaplatin
  • [Number-of-references] 11
  •  go-up   go-down


29. Pailler MC, Benichou M: [Treatment of locally advanced or metastatic non-small cell bronchial cancer]. Rev Pneumol Clin; 2000 Dec;Suppl 3:13-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of locally advanced or metastatic non-small cell bronchial cancer].
  • [Transliterated title] Traitement des cancers bronchiques non à petites cellules localement évolués ou métastiques.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bronchial Neoplasms / drug therapy. Bronchial Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11280973.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement